WO2007105015A3 - DERIVATIVES OF 18ß-GLYCYRRHETINIC ACID - Google Patents

DERIVATIVES OF 18ß-GLYCYRRHETINIC ACID Download PDF

Info

Publication number
WO2007105015A3
WO2007105015A3 PCT/GB2007/050118 GB2007050118W WO2007105015A3 WO 2007105015 A3 WO2007105015 A3 WO 2007105015A3 GB 2007050118 W GB2007050118 W GB 2007050118W WO 2007105015 A3 WO2007105015 A3 WO 2007105015A3
Authority
WO
WIPO (PCT)
Prior art keywords
derivatives
present
glycyrrhetinic acid
methods
relates
Prior art date
Application number
PCT/GB2007/050118
Other languages
French (fr)
Other versions
WO2007105015A2 (en
Inventor
Simon Ward
Alice Macgowan
Stanley Roberts
Jenny Littlechild
Kirsty Line
Ed Irving
Sam Donnelly
Original Assignee
York Pharma Plc
Simon Ward
Alice Macgowan
Stanley Roberts
Jenny Littlechild
Kirsty Line
Ed Irving
Sam Donnelly
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by York Pharma Plc, Simon Ward, Alice Macgowan, Stanley Roberts, Jenny Littlechild, Kirsty Line, Ed Irving, Sam Donnelly filed Critical York Pharma Plc
Priority to EP07733544A priority Critical patent/EP1994044A2/en
Priority to JP2008558912A priority patent/JP2009529572A/en
Publication of WO2007105015A2 publication Critical patent/WO2007105015A2/en
Publication of WO2007105015A3 publication Critical patent/WO2007105015A3/en
Priority to US12/207,899 priority patent/US20090076032A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to novel derivatives of 18β-glycyrrhetinic acid and methods of synthesising the derivatives. Also included within the scope of the present invention are pharmaceutical compositions comprising the derivatives of the present invention and medical uses of the derivatives, including their use in inhibiting enzymes such as retinol dehydrogenases. The present invention also relates to methods of treating diseases, such as hyperproliferative diseases, neoplasms, cancers and photoageing.
PCT/GB2007/050118 2006-03-10 2007-03-09 DERIVATIVES OF 18ß-GLYCYRRHETINIC ACID WO2007105015A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP07733544A EP1994044A2 (en) 2006-03-10 2007-03-09 DERIVATIVES OF 18ß-GLYCYRRHETINIC ACID
JP2008558912A JP2009529572A (en) 2006-03-10 2007-03-09 Derivatives of 18β-glycyrrhetinic acid
US12/207,899 US20090076032A1 (en) 2006-03-10 2008-09-10 Derivatives of 18Beta-Glycyrrhetinic Acid

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0604899.5A GB0604899D0 (en) 2006-03-10 2006-03-10 Derivatives of 18-glycyrrhetinic acid
GB0604899.5 2006-03-10
GBGB0624963.5A GB0624963D0 (en) 2006-03-10 2006-12-15 Derivatives of 188-Glycyrrhetinic Acid
GB0624963.5 2006-12-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/207,899 Continuation US20090076032A1 (en) 2006-03-10 2008-09-10 Derivatives of 18Beta-Glycyrrhetinic Acid

Publications (2)

Publication Number Publication Date
WO2007105015A2 WO2007105015A2 (en) 2007-09-20
WO2007105015A3 true WO2007105015A3 (en) 2008-03-27

Family

ID=36241409

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/050118 WO2007105015A2 (en) 2006-03-10 2007-03-09 DERIVATIVES OF 18ß-GLYCYRRHETINIC ACID

Country Status (5)

Country Link
US (1) US20090076032A1 (en)
EP (1) EP1994044A2 (en)
JP (1) JP2009529572A (en)
GB (2) GB0604899D0 (en)
WO (1) WO2007105015A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4649549B2 (en) * 2008-07-16 2011-03-09 国立大学法人名古屋大学 Glycyrrhetinic acid derivative and use thereof
US9416151B2 (en) 2010-08-25 2016-08-16 Lurong ZHANG Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis
TWI424839B (en) 2011-10-27 2014-02-01 Univ Kaohsiung Medical 18β-glycyrrhetinic acid derivatives and its usage thereof
FR2996135A1 (en) * 2012-09-28 2014-04-04 Inneov Lab ORAL COMPOSITION FOR ENHANCING SKIN TOLERANCE FOLLOWING TOPICAL ADMINISTRATION OF RETINOID COMPOUND
CN104672293B (en) * 2013-11-30 2017-01-18 苏州博创园生物医药科技有限公司 Pentacyclic triterpene structure modified compound as well as preparation method and application thereof
CA2974066A1 (en) * 2014-12-25 2016-06-30 International Institute Of Cancer Immunology, Inc. Method for modifying t cell population
CN106749481A (en) * 2015-11-20 2017-05-31 刘力 Enoxolone class noval chemical compound entity and application thereof
DK3539974T5 (en) * 2016-11-09 2024-05-27 Osaka Univ Method for modifying t cell population
EA202090438A1 (en) 2017-08-04 2020-06-15 Арделикс, Инк. Glycerretic Acid Derivatives for the Treatment of Hyperkalemia
CN108794564B (en) * 2018-08-03 2021-01-19 烟台大学 Hederagenin A-ring-and-pyrazine derivative as well as preparation method and application thereof
AU2020218255A1 (en) 2019-02-07 2021-09-09 Ardelyx, Inc. Glycyrrhetinic acid derivatives for use in treating hyperkalemia
EP4326247A1 (en) * 2021-04-23 2024-02-28 Helmholtz-Zentrum für Infektionsforschung GmbH Citraconic acid and derivatives thereof for use as a medicament

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1076684B (en) * 1957-07-16 1960-03-03 Biorex Laboratories Ltd Process for the preparation of pharmacologically active compounds of glycyrrhetinic acid
FR391M (en) * 1959-03-10 1961-04-10
GB1387499A (en) * 1972-09-06 1975-03-19 Biorex Laboratories Ltd Derivatives of glycyrrhetinic acid
EP0069380A1 (en) * 1981-07-06 1983-01-12 Maruzen Pharmaceutical Co., Ltd. 11-Deoxoglycyrrhetinic acid hydrogen maleate, process for its production, and its use as a medicine
GB2144746A (en) * 1983-08-12 1985-03-13 Biorex Laboratories Ltd Diastereoisomers of glycyrrhetinic acid derivatives
US4548950A (en) * 1982-06-30 1985-10-22 Biorex Laboratories Limited Pharmaceutical composition
EP0272478A1 (en) * 1986-11-28 1988-06-29 Sanwa Kagaku Kenkyusho Co., Ltd. Glycyrrhetic acid derivatives and use thereof
EP0518533A1 (en) * 1991-05-30 1992-12-16 Sanwa Kagaku Kenkyusho Co., Ltd. Glycyrrhetinic acid derivatives and antiviral compositions thereof
WO1998058946A1 (en) * 1997-06-24 1998-12-30 Nippon Shinyaku Co., Ltd. Triterpene derivatives and medicinal composition
EP1419777A1 (en) * 2002-10-29 2004-05-19 Minophagen Pharmaceutical Co., Ltd. Use of glycyrrhizin and its derivatives as MCP-1 production inhibitors
EP1421942A1 (en) * 2002-10-29 2004-05-26 Minophagen Pharmaceutical Co., Ltd. Use of glycyrrhizin and its derivatives as RANTES inducers
WO2005030790A1 (en) * 2003-09-26 2005-04-07 Panacos Pharmaceuticals, Inc. Novel triterpene derivatives, preparation thereof and use thereof
WO2005123649A1 (en) * 2004-06-18 2005-12-29 Ganga Raju Gokaraju NOVEL ANALOGS OF 3-O-ACETYL-11-KETO-β-BOSWELLIC ACID

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04352755A (en) * 1991-05-30 1992-12-07 Sanwa Kagaku Kenkyusho Co Ltd Antiviral agent comprising glycyrrhizic acid derivative as active ingredient
GB0020351D0 (en) * 2000-08-17 2000-10-04 Catalyst Biomedica Ltd Treatment of hyperproliferative diseases

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1076684B (en) * 1957-07-16 1960-03-03 Biorex Laboratories Ltd Process for the preparation of pharmacologically active compounds of glycyrrhetinic acid
FR391M (en) * 1959-03-10 1961-04-10
GB1387499A (en) * 1972-09-06 1975-03-19 Biorex Laboratories Ltd Derivatives of glycyrrhetinic acid
US3873599A (en) * 1972-09-06 1975-03-25 Biorex Laboratories Ltd New derivatives of glycyrrhetinic acid
EP0069380A1 (en) * 1981-07-06 1983-01-12 Maruzen Pharmaceutical Co., Ltd. 11-Deoxoglycyrrhetinic acid hydrogen maleate, process for its production, and its use as a medicine
US4548950A (en) * 1982-06-30 1985-10-22 Biorex Laboratories Limited Pharmaceutical composition
GB2144746A (en) * 1983-08-12 1985-03-13 Biorex Laboratories Ltd Diastereoisomers of glycyrrhetinic acid derivatives
EP0272478A1 (en) * 1986-11-28 1988-06-29 Sanwa Kagaku Kenkyusho Co., Ltd. Glycyrrhetic acid derivatives and use thereof
EP0518533A1 (en) * 1991-05-30 1992-12-16 Sanwa Kagaku Kenkyusho Co., Ltd. Glycyrrhetinic acid derivatives and antiviral compositions thereof
WO1998058946A1 (en) * 1997-06-24 1998-12-30 Nippon Shinyaku Co., Ltd. Triterpene derivatives and medicinal composition
EP1419777A1 (en) * 2002-10-29 2004-05-19 Minophagen Pharmaceutical Co., Ltd. Use of glycyrrhizin and its derivatives as MCP-1 production inhibitors
EP1421942A1 (en) * 2002-10-29 2004-05-26 Minophagen Pharmaceutical Co., Ltd. Use of glycyrrhizin and its derivatives as RANTES inducers
WO2005030790A1 (en) * 2003-09-26 2005-04-07 Panacos Pharmaceuticals, Inc. Novel triterpene derivatives, preparation thereof and use thereof
WO2005123649A1 (en) * 2004-06-18 2005-12-29 Ganga Raju Gokaraju NOVEL ANALOGS OF 3-O-ACETYL-11-KETO-β-BOSWELLIC ACID

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
ASSEFA H ET AL: "Synthesis and evaluation of potential complement inhibitory semisynthetic analogs of oleanolic acid", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 9, no. 14, 19 July 1999 (1999-07-19), pages 1889 - 1894, XP004171604, ISSN: 0960-894X *
DARGAN D J ET AL: "The effect of triterpenoid compounds on uninfected and herpes simplex virus-infected cells in culture.I.Effect on cell growth,virus particles and virus replication", JOURNAL OF GENERAL VIROLOGY, READING, BERKS, GB, vol. 66, no. 8, 1985, pages 1771 - 1784, XP008081202, ISSN: 0022-1317 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; CHOW, S. Y. ET AL: "Protective effects of glycyrrhetic acid derivatives on the exogenous gastric ulcer in rats", XP002446214, retrieved from STN Database accession no. 1977:177203 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SEGAWA, JUN ET AL: "Triterpene derivatives and medicinal composition", XP002465200, retrieved from STN Database accession no. 1999:27844 *
DAVIDSON, JAMES S. ET AL: "Glycyrrhetinic acid derivatives: a novel class of inhibitors of gap-junctional intercellular communication. Structure-activity relationships", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS , 246(3), 1104-7 CODEN: JPETAB; ISSN: 0022-3565, 1988, XP008082268 *
HARADA S ET AL: "Biochemical characterization of recombinant HIV-1 reverse transcriptase (rRT) as a glycyrrhizin-binding protein and the CK-II-mediated stimulation of rRT activity potently inhibited by glycyrrhetinic acid derivative.", BIOLOGICAL & PHARMACEUTICAL BULLETIN DEC 1998, vol. 21, no. 12, December 1998 (1998-12-01), pages 1282 - 1285, XP002465199, ISSN: 0918-6158 *
INOUE H ET AL: "INHIBITORY EFFECT OF GLYCYRRHETINIC ACID DERIVATIVES ON LIPOXYGENASE AND PROSTAGLANDIN SYNTHETASE", CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO, JP, vol. 34, no. 2, 1986, pages 897 - 901, XP001180560, ISSN: 0009-2363 *
KASHIWADA, YOSHIKI ET AL: "Anti-AIDS Agents 38. Anti-HIV Activity of 3-O-Acylursolic acid Derivatives", JOURNAL OF NATURAL PRODUCTS , 63(12), 1619-1622 CODEN: JNPRDF; ISSN: 0163-3864, 2000, XP002465196 *
KHAKSA G ET AL: "Anti-inflammatory and anti-nociceptive activity of disodium glycyrrhetinic acid hemiphthalate", PLANTA MEDICA, THIEME, STUTTGART, DE, vol. 62, no. 4, 1996, pages 326 - 328, XP008086714, ISSN: 0032-0943 *
KONDRATENKO R M ET AL: "Synthesis and antiulcer activity of 3-O-acylated glycyrrhetic acid methylates", PHARMACEUTICAL CHEMISTRY JOURNAL 2001 UNITED STATES, vol. 35, no. 5, 2001, pages 243 - 246, XP002465195, ISSN: 0091-150X *
MERCIER, F. ET AL: "Experimental study of several nonsteroidal antiinflammatory drugs or combinations", INTERN. SYMP. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, MILAN , VOLUME DATE 1964 252-8, 1965, XP008087447 *
SEGAL, RUTH ET AL: "Effect of ester groups on the hemolytic action of sapogenins. II. Esterification with bifunctional acids", BIOCHEMICAL PHARMACOLOGY , 19(8), 2501-7 CODEN: BCPCA6; ISSN: 0006-2952, 1970, XP002465193 *
SERRA, C. ET AL: "Antiviral activity of new triterpenic derivatives", PHARMACOLOGICAL RESEARCH , 29(4), 359-66 CODEN: PHMREP; ISSN: 1043-6618, 1994, XP002446212 *
SHAMSA, FAZEL ET AL: "The in vitro effects of glycyrrhizin and the derivatives of glycyrrhetinic acid on the activity of cAMP-dependent protein kinase and phosphorylation of cellular polypeptide by the kinase from Ehrlich ascites tumor cells", TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE , 165(4), 305-18 CODEN: TJEMAO; ISSN: 0040-8727, 1991, XP002465194 *
TOYOSHIMA, TOSHINOBU ET AL: "An implication of molecular mechanism for eliciting sweetness of anionic .beta.-glycyrrhetinic acid derivatives", JOURNAL OF OLEO SCIENCE , 51(5), 313-321 CODEN: JOSOAP; ISSN: 1345-8957, 2002, XP008082270 *
TSUKAHARA MICHIKO ET AL: "Synthesis and inhibitory effect of novel glycyrrhetinic acid derivatives on IL-1 beta-induced prostaglandin E(2) production in normal human dermal fibroblasts.", CHEMICAL & PHARMACEUTICAL BULLETIN SEP 2005, vol. 53, no. 9, September 2005 (2005-09-01), pages 1103 - 1110, XP002465198, ISSN: 0009-2363 *
YU, DONGLEI ET AL: "Anti-AIDS Agents 69. Moronic Acid and Other Triterpene Derivatives as Novel Potent Anti-HIV Agents", JOURNAL OF MEDICINAL CHEMISTRY , 49(18), 5462-5469 CODEN: JMCMAR; ISSN: 0022-2623, 15 August 2006 (2006-08-15), XP002465197 *
ZHONGHUA YIXUE ZAZHI (TAIPEI) , 23(4), 217-23 CODEN: CIHCDM; ISSN: 0578-1337, 1976 *
ZHU Y-M ET AL: "Synthesis and Anti-HIV Activity of Oleanolic Acid Derivatives", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 11, no. 24, December 2001 (2001-12-01), pages 3115 - 3118, XP002984538, ISSN: 0960-894X *

Also Published As

Publication number Publication date
GB0624963D0 (en) 2007-01-24
GB0604899D0 (en) 2006-04-19
JP2009529572A (en) 2009-08-20
WO2007105015A2 (en) 2007-09-20
EP1994044A2 (en) 2008-11-26
US20090076032A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
WO2007105015A3 (en) DERIVATIVES OF 18ß-GLYCYRRHETINIC ACID
WO2006099169A3 (en) Novel liposome compositions
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
MX2009006704A (en) New compounds.
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
WO2010078421A8 (en) Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds
WO2006086562A3 (en) Phenylazetidinone derivatives
WO2011082273A3 (en) Substituted pyrrolo-aminopyrimidine compounds
WO2011082266A3 (en) Substituted heterocyclic compounds
WO2011082270A3 (en) Substituted imidazopyridinyl-aminopyridine compounds
WO2008132229A3 (en) Highly concentrated insulin solutions and compositions
WO2011082267A3 (en) Substituted triazolo-pyrazine compounds
TW200724537A (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
TW200730518A (en) Crystalline forms of docetaxel and processes for their preparation
WO2007093880A3 (en) Novel pyrone-indole derivatives and process for their preparation
WO2008086462A3 (en) AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
WO2008030818A3 (en) Novel liposome compositions
MX2010000266A (en) A method for decreasing symptoms of alcohol consumption.
WO2008022345A3 (en) Compositions and methods for inhibiting cytochrome p450
JO2721B1 (en) Artemisinin Derivative Dimers, Their preparation and their therapeutic application
WO2009062576A8 (en) Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same
WO2009115084A3 (en) Pyrrolopyrimidine derivatives, and use thereof
JO2682B1 (en) 7-ALkynyl-1,8-Naphthyridone Derivatives, Preparation Thereof And Therapeutic Use Thereof
WO2009099553A3 (en) Use of kinase inhibitor in treatment of atherosclerosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07733544

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008558912

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007733544

Country of ref document: EP